

the **ADBL** report

Issue #134, September 2023

An Official Accompaniment to the Alberta Drug Benefit List (ADBL) produced by Alberta Blue Cross

The Expert Committee on Drug Evaluation and Therapeutics (ECDET)

EXPERT COMMITTEE MEMBERS:

Fiona Clement, PhD, (Chair)
Micheal Guirguis, BScPharm, PhD (Vice-Chair)
Daniel Altman, BSc, MD, FRCPC
Caitlin A. Clarke, BScPhm, PharmD
Margaret Gray, BSP, FCSHP
Michael Kolber, BSc, MD, CCFP, MSc
Naeem Ladhani, BScPharm
Nicholas Myers, BSc, MB, BS, MRCGP (UK)
Tony Nickonchuk, BScPharm

ALBERTA HEALTH LIAISON:

Andrea Nagle, BScPharm, LLB

ADMINISTRATIVE AND SCIENTIFIC SUPPORT:

Julia Chan, BSc (Pharm)
Amanda Chung, BSc (Pharm)
Sherry Dieleman, BSc (Pharm), MSc
Amina Babar, BSc (Pharm)

In this issue:

- *Brief Summary of Drug Review Activities*
- *Highlights of:*
 - ❖ *Products Originally Reviewed by CADTH*
 - ❖ *Drug Products Added*
 - ❖ *Interchangeable Drug Products Added*
 - ❖ *Biosimilar Drug Products Added*
 - ❖ *Changes to Currently Listed Products*
- *Special Authorization Criteria Changes*

Brief Summary of Drug Review Activities

The Expert Committee on Drug Evaluation and Therapeutics met on July 20, 2023. The Committee reviewed Manufacturer submissions for thirty-five (35) Drug Products for potential listing, or change in listing, on the ADBL. The Committee also considered information for a number of supplementary assessments of the coverage status of ninety-six (96) Drug Products.

In addition to Drug Products reviewed by the Expert Committee, ten (10) Drug Products and Devices underwent Expedited Review for listing on the ADBL effective August 1, 2023, and ten (10) Drug Products and Devices underwent Expedited Review for listing on the ADBL effective September 1, 2023.

The following are highlights of recent changes to the ADBL and other topics of general interest. A complete list of changes, as well as the full ADBL may be accessed at

<https://www.ab.bluecross.ca/dbl/publications.php>

Highlights of Products Originally Reviewed by the Canadian Agency for Drugs and Technologies in Health (CADTH)

The following Drug Products were reviewed by CADTH and the Expert Committee and added to the ADBL effective August 1, 2023:

- **ALBRIOZA* 3 g/1 g oral powder packet** (sodium phenylbutyrate/ ursodoxicoltaurine) (AYX) via Special Authorization (SA)
- **RADICAVA* 105 mg/5 mL oral suspension** (edaravone) (MIT) via SA
- **VYEPTI* 100 mg/1 mL vial injection** (eptinezumab) (LBC) via SA

A complete list of changes, as well as the full ADBL may be accessed at <https://www.ab.bluecross.ca/dbl/publications.php>.

Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).

The following Drug Products were reviewed by CADTH and the Expert Committee and added to the *ADBL* effective September 1, 2023:

- **CIBINQO* 50 mg, 100 mg & 200 mg tablets** (abrocitinib) (PFI) via SA
- **TREMFYA* 100 mg/mL injection syringe & TREMFYA ONE-PRESS* 100 mg/mL auto-injector syringe** (guselkumab) (JAI) via SA

Highlights of Drug Products Added

The following Drug Products were reviewed by the Expert Committee and added to the *ADBL* effective September 1, 2023:

- **ACUVAIL 0.45% ophthalmic solution** (ketorolac tromethamine) (ABV)
- **M-HC 1% urea 10% topical cream** (hydrocortisone acetate/ urea) (MTR)

Highlights of Interchangeable (IC) Drug Products Added

Addition of the following Entry IC Drug Products to the *ADBL* has resulted in the creation of New IC Groupings, effective September 1, 2023:

- **DAPAGLIFLOZIN 5 mg & 10 mg tablets** (various brands: APX, AUR, GLM, JPC, MTR, PMS & SDZ)
- **AURO-DAPAGLIFLOZIN/ METFORMIN 5 mg/850 mg & 5 mg/1000 mg tablets** (dapagliflozin/ metformin hydrochloride) (AUR)

Highlights of Biosimilar Drug Products Added

The following Biosimilar Drug Product was added to the *ADBL* effective September 1, 2023:

- **LAPELGA* 6 mg/0.6 mL pre-filled autoinjector** (pegfilgrastim) (APX) via SA

Highlights of Changes to Currently Listed Products

The coverage status of the following Drug Products have been revised from Step Therapy/Special Authorization to a Regular Benefit effective September 1, 2023:

- **FORXIGA 5 mg & 10 mg tablets** (dapagliflozin) (AZC)
- **XIGDUO 5 mg/850 mg & 5 mg/1000 mg tablets** (dapagliflozin/ metformin hydrochloride) (AZC)

Special Authorization Criteria Changes

The Special Authorization criteria for coverage for the following Drug Products have been revised effective September 1, 2023:

- **RADICAVA* 105 mg/5 mL oral suspension & 0.3 mg/mL injection** (edaravone) (MIT)

A complete list of changes, as well as the full *ADBL* may be accessed at <https://www.ab.bluecross.ca/dbl/publications.html>.

*Please refer to the current *ADBL* for explanations of coverage, including a listing of coverage criteria (where applicable).*